Laryngeal carcinoma lymph node metastasis and disease-free survival correlate with MASPIN nuclear expression but not with EGFR expression: A series of 108 cases

European Archives of Oto-Rhino-Laryngology

Volumn 267, Issue 7, 2010, Pages 1103-1110

  Marioni, Gino ^a   Staffieri, Alberto ^a   Bertolin, Andy ^b   Giacomelli, Luciano ^a   D'Alessandro, Emiliano ^a   Ottaviano, Giancarlo ^a   Accordi, Daria ^a   Stramare, Roberto ^a   De Filippis, Cosimo ^a   Blandamura, Stella ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Vittorio Veneto Hospital   (Italy)

Author keywords

EGFR; Laryngeal carcinoma; MASPIN; Prognosis; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MASPIN;

ADULT; ARTICLE; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CELL NUCLEUS; COMPUTER ANALYSIS; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LARYNGECTOMY; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECURRENCE RISK; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; BIOPSY; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; DIAGNOSTIC IMAGING; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LARYNGEAL NEOPLASMS; LARYNGECTOMY; LARYNGOSCOPY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SERPINS;

EID: 77955094230     PISSN: 09374477     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00405-009-1186-2     Document Type: Article

References (25)

1. Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A (2006) Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev 32:504-515.
2. Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H, Carlsson J (2008) EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol 15:1193-1201.
3. Boonstra J, Rijken P, Humbel B, Cremers F, Verkleij A, van Bergen en Henegouwen P (1995) The epidermal growth factor. Cell Biol Int 19:413-430.
4. West CM, Joseph L, Bhana S (2008) Epidermal growth factor receptor-targeted therapy. Br J Radiol 81(Spec No 1):S36-S44.
5. Licitra L, Locati L, Bossi P (2006) Biological agents in head and neck cancer. Ann Oncol 17(Suppl 10):x45-x48.
6. Khalkhali-Ellis Z (2006) Maspin: the new frontier. Clin Cancer Res 12:7279-7283.
7. Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ (2006) Biological functions of MASPIN. J Cell Physiol 209:617-624.
8. Lonardo F, Li X, Siddiq F et al (2006) Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer 51:31-39.
9. Marioni G, Staffieri C, Staffieri A, de Filippis C, Blandamura S (2009) MASPIN tumour-suppressing activity in head and neck squamous cell carcinoma. Emerging evidences and therapeutic perspectives. Acta Otolaryngol (Stockh) 129:476-480.
10. International Union Against Cancer (1997) TNM classiffication of malignant tumours, 5th edn. Wiley-Liss, New York.
11. Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92:1331-1346.
12. Inouè S, Spring KR (1986) Video microscopy. The fundamentals, 2nd edn. Plenum Press, New York.
13. Shannon CE (1949) Communication in the presence of noise. Proc Inst Radio Eng 37:10-21.
14. Dietz A, Boehm A, Mozet C, Wichmann G, Giannis A (2008) Current aspects of targeted therapy in head and neck tumors. Eur Arch Otorhinolaryngol 265(Suppl 1):S3-S12.
15. Almadori G, Cadoni G, Galli J et al (1999) Epidermal growth factor receptor expression in primary laryngeal cancer: an independent prognostic factor of neck node relapse. Int J Cancer 84:188-191.
16. Vlachtsis K, Nikolaou A, Markou K, Fountzilas G, Daniilidis I (2005) Clinical and molecular prognostic factors in operable laryngeal cancer. Eur Arch Otorhinolaryngol 262:890-898.
17. Jiang H, Yang B-B (2009) p53, epidermal growth factor receptor and proliferating cell nuclear antigen in laryngeal squamous cell carcinoma are not predictive markers for the effect of adjuvant radiotherapy. Acta Otolaryngol (Stockh) 129:101-107.
18. Pivot X, Magné N, Guardiola E et al (2005) Prognostic impact of epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral Oncol 41:320-327. (Pubitemid 40320461)
19. Marioni G, Blandamura S, Giacomelli L et al (2005) Nuclear expression of MASPIN is associated with a lower recurrence rate and a longer disease free interval after surgery for squamous cell carcinoma of the larynx. Histopathology 46:576-582.
20. Jang HL, Nam E, Lee KH, Yeom S, Son HJ, Park C (2008) Maspin polymorphism associated with apoptosis susceptibility and in vivo tumorigenesis. Int J Mol Med 22:333-338.
21. Marioni G, D'Alessandro E, Giacomelli L et al (2006) Maspin nuclear localization is related to reduced density of tumour-associated microvessels in laryngeal carcinoma. Anticancer Res 26:4927-4932.
22. Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF (2004) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 17:197-203.
23. Marioni G, Ottaviano G, Giacomelli L et al (2006) CD105-assessed micro-vessel density is associated with malignancy recurrence in laryngeal squamous cell carcinoma. Eur J Surg Oncol 32:1149-1153.
24. Marioni G, Giacomelli L, D'Alessandro E et al (2008) Nuclear localization of mammary serine protease inhibitor (MASPIN): is its impact on the prognosis in laryngeal carcinoma due to a proapoptotic effect? Am J Otolaryngol 29:156-162.
25. Beltran A, Parikh S, Liu Y et al (2007) Re-activation of a dormant tumor suppressor gene MASPIN by designed transcription factors. Oncogene 26:2791-2798.